DeepMind spinout Isomorphic Labs raised $2.1 billion as Demis Hassabis now points to first AI-designed drugs entering human trials by late 2026.
變化在哪裡
The company uses IsoDDE, a pipeline combining structure prediction, molecule generation, binding prediction and ADMET assessment.
Thrive, Alphabet-linked funds, MGX, Temasek and a UK sovereign AI fund joined the round, showing the capital intensity of AI drug discovery.
為什麼重要
Entering clinical trials is not the same as approval; the pharmaceutical probability game remains slow and harsh.
接下來看什麼
真正值得看的不是標題上的數字，而是產品、合約或平台轉向能否在接下來兩個季度形成可重複的曲線。
參考來源: CocoLoop